Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA6 | P23280 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245736 | 0.91 | CA1 (0.52) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL2380940 | 0.91 | NPSR1 (0.45) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL14571334 | 0.86 | ALDH1A1 (0.57) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL2380600 | 0.86 | TSHR (0.52) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL2382409 | 0.84 | NPSR1 (0.63) | ALDH1A1GAASMN1; SMN2NPSR1TSHR | |
| SCHEMBL12245738 | 0.75 | KMT2A (0.59) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL6273571 | 0.74 | ALDH1A1 (0.62) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL6271004 | 0.74 | ALDH1A1 (0.76) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL12245740 | 0.73 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2NPSR1TSHRHTT | |
| SCHEMBL19793283 | 0.73 | MAPK1 (0.70) | ALDH1A1CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1896461-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | Amgen Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | ALDH1A1 369/4885CA1 4700/4885CA2 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.